scholarly journals Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia

Blood ◽  
2018 ◽  
Vol 131 (12) ◽  
pp. 1337-1349 ◽  
Author(s):  
Julia C. Gutjahr ◽  
Eva Szenes ◽  
Lisa Tschech ◽  
Daniela Asslaber ◽  
Michaela Schlederer ◽  
...  

Key PointsThe spleen but not bone marrow microenvironment induces CD44v6 variants in CLL, which promote early engraftment. CD44v6 expression is linked to NF-κB and MAPK signaling in murine and human B-cell leukemia and contributes to proliferation.

Blood ◽  
2014 ◽  
Vol 123 (24) ◽  
pp. 3727-3732 ◽  
Author(s):  
Paolo Strati ◽  
Michael J. Keating ◽  
Susan M. O'Brien ◽  
Jan Burger ◽  
Alessandra Ferrajoli ◽  
...  

Key Points MRD eradication is a desirable end point in chronic lymphocytic leukemia. Early MRD eradication may prompt treatment discontinuation.


Blood ◽  
2017 ◽  
Vol 130 (18) ◽  
pp. 2006-2017 ◽  
Author(s):  
Vanessa Zurli ◽  
Giuliana Wimmer ◽  
Francesca Cattaneo ◽  
Veronica Candi ◽  
Emanuele Cencini ◽  
...  

Key Points ILT3 is ectopically expressed on mature CLL cells and CLL progenitors in the bone marrow. ILT3 controls the activation of Akt kinase in CLL and contributes to a regulatory network defined by a SHIP-1/Deltex1 axis.


2002 ◽  
Vol 71 (4) ◽  
pp. 306-310 ◽  
Author(s):  
Salwa S. Sheikh ◽  
Bhaskar V.S. Kallakury ◽  
Khawla A. Al-Kuraya ◽  
Jeanne Meck ◽  
Dan P. Hartmann ◽  
...  

2021 ◽  
Vol 10 (4) ◽  
pp. 867
Author(s):  
Katarzyna Skorka ◽  
Paulina Wlasiuk ◽  
Agnieszka Karczmarczyk ◽  
Krzysztof Giannopoulos

Functional toll-like receptors (TLRs) could modulate anti-tumor effects by activating inflammatory cytokines and the cytotoxic T-cells response. However, excessive TLR expression could promote tumor progression, since TLR-induced inflammation might stimulate cancer cells expansion into the microenvironment. Myd88 is involved in activation NF-κB through TLRs downstream signaling, hence in the current study we provided, for the first time, a complex characterization of expression of TLR2, TLR4, TLR7, TLR9, and MYD88 as well as their splicing forms in two distinct compartments of the microenvironment of chronic lymphocytic leukemia (CLL): peripheral blood and bone marrow. We found correlations between MYD88 and TLRs expressions in both compartments, indicating their relevant cooperation in CLL. The MYD88 expression was higher in CLL patients compared to healthy volunteers (HVs) (0.1780 vs. 0.128, p < 0.0001). The TLRs expression was aberrant in CLL compared to HVs. Analysis of survival curves revealed a shorter time to first treatment in the group of patients with low level of TLR4(3) expression compared to high level of TLR4(3) expression in bone marrow (13 months vs. 48 months, p = 0.0207). We suggest that TLRs expression is differentially regulated in CLL but is similarly shared between two distinct compartments of the microenvironment.


Blood ◽  
2013 ◽  
Vol 121 (14) ◽  
pp. 2704-2714 ◽  
Author(s):  
Alan G. Ramsay ◽  
Rachel Evans ◽  
Shahryar Kiaii ◽  
Lena Svensson ◽  
Nancy Hogg ◽  
...  

Key Points CLL cells induce defects in T-cell LFA-1–mediated migration by altering Rho GTPase activation signaling, downregulating RhoA and Rac1, and upregulating Cdc42. Lenalidomide repairs these T-cell defects by restoring normal Rho GTPase activation signaling.


2017 ◽  
Vol 59 (7) ◽  
pp. 1565-1573 ◽  
Author(s):  
Ashima Shukla ◽  
Vipul Shukla ◽  
Shantaram S. Joshi

2005 ◽  
Vol 23 (24) ◽  
pp. 5788-5794 ◽  
Author(s):  
Steven Z. Pavletic ◽  
Issa F. Khouri ◽  
Michael Haagenson ◽  
Roberta J. King ◽  
Philip J. Bierman ◽  
...  

Purpose To determine the role of myeloablative conditioning and unrelated donor (URD) bone marrow transplantation in the treatment of patients with advanced B-cell chronic lymphocytic leukemia (CLL). Patients and Methods A total of 38 CLL patients received a matched URD transplant using bone marrow procured by the National Marrow Donor Program. The median age was 45 years (range, 26 to 57 years), the median time from diagnosis was 51 months, and the median number of prior chemotherapy regimens was three. Fifty-five percent of patients were chemotherapy refractory and 89% had received fludarabine. Conditioning included total-body irradiation in 92% of patients. Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate with cyclosporine or tacrolimus for 82% of patients. Results Twenty-one patients (58%) achieved complete response and six (17%) achieved partial response. Incidences of grades 2 to 4 acute GVHD were 45% at 100 days and incidences of chronic GVHD were 85% at 5 years. Eleven patients are alive and disease free at a median of 6 years (range, 3.0 to 9.0 years). Five-year overall survival, failure-free survival, disease progression rates, and treatment-related mortality (TRM) were 33%, 30%, 32%, and 38% respectively. Conclusion These data demonstrate that lasting remissions can be achieved after URD transplantation in patients with advanced CLL. High TRM suggest that myeloablative conditioning and HLA-mismatched donors should be avoided in future protocols, and it is mandatory to investigate transplant strategies with a lower morbidity and mortality, including the use of nonmyeloablative regimens.


2014 ◽  
Vol 7 (4) ◽  
pp. 189-193
Author(s):  
Chelsea Hayes ◽  
Yao Ma ◽  
Maria Delioukina ◽  
Serhan Alkan ◽  
Qin Huang

Sign in / Sign up

Export Citation Format

Share Document